NAPLES, Fla. and CAMBRIDGE, United Kingdom — January 2, 2026 — Leads & Copy — CDT Equity Inc. (Nasdaq: CDT) has engaged NJS Foresight Bio-Advisory, LLC, to identify, source, and support the execution of out-licensing opportunities for selected assets within its solid-form patent portfolio. The engagement is intended to expand CDT’s commercial reach and accelerate potential licensing and royalty-based transactions.
NJS Foresight Bio-Advisory, LLC brings more than 20 years of out-licensing experience and has completed numerous successful licensing agreements across the biotechnology and pharmaceutical sectors. The firm’s principal, Dr. Nicholas J. Sarlis, brings over 25 years of clinical and pharmaceutical/biotechnology expertise to the role, including leadership of multidisciplinary teams advancing early and late-stage development programs, involvement in the successful launch of six global products, and direct participation in more than thirty clinical studies. He holds medical and doctoral degrees from the University of Athens and a PhD from Imperial College London, and is board certified in Internal Medicine in the United States. He is a Fellow of both the American College of Physicians and the Royal Society of Medicine.
CDT has built a portfolio of solid-form patents including cocrystals and salts that deliver enhanced physicochemical properties such as improved solubility, bioavailability and alternative delivery modes. These solid-forms also carry up to twenty years of patent protection, creating a pathway for partners to extend product lifecycles beyond traditional patent expiry.
The Company has been actively reviewing opportunities where marketed products face significant patent cliffs and where CDT has developed differentiated solid-forms of these active pharmaceutical ingredients. Industry data indicates a renewed period of investment activity in biopharma as companies respond to patent expirations, strategic consolidation and the adoption of AI-driven technologies. CDT believes these trends create a constructive environment for solid-form innovation and out-licensing.
Dr. Andrew Regan, Chief Executive Officer of CDT, said CDT continues to assess commercial pathways for its portfolio and sees strong potential for its solid-form assets to support lifecycle management strategies across the sector.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. In parallel, CDT has implemented a cryptocurrency treasury reserve strategy, initially focused on Bitcoin (BTC), designed to diversify its capital allocation and strengthen its financial position. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
CDT Equity Inc. can be contacted at Info@cdtequity.com.
Source: CDT Equity Inc.
